Analgesia News and Research

RSS

Positive results from Phase 2 clinical trial of ARX-03 announced

AcelRx Pharmaceuticals, Inc. today announced positive results from a Phase 2 clinical trial of ARX-03, a proprietary sublingual dosage form combining an opioid, sufentanil, with a benzodiazepine, triazolam.

23 Oct 2009

Genesis Health System implements AeroScout's hospital-wide asset tracking and management system

AeroScout, the leading provider of Unified Asset Visibility for the healthcare industry, today announced that Genesis Health System has implemented AeroScout’s Wi-Fi RTLS (real time location system) for hospital-wide asset tracking and management at Genesis Medical Center in Davenport, Iowa. Genesis uses the AeroScout solution to improve staff efficiency, optimize maintenance of medical equipment and reduce operational and capital expenses associated with renting additional devices and purchasing equipment.

21 Oct 2009

UF scientists shed new light on old medical procedure

You might not know what it's called, but if you've had general anesthesia before surgery, especially after an accident, it is likely you have received Sellick's maneuver. That's when fingers are pressed against a patient's throat to prevent regurgitation and spilling of stomach contents into the airway and lungs while anesthesia is being administered.

21 Oct 2009

Cumberland Pharmaceuticals publishes data on its Phase III intravenous ibuprofen study

Cumberland Pharmaceuticals Inc. announced today that its Phase III study on intravenous ibuprofen as a post-operative analgesic was published in Volume 31, Number 9 of the peer-reviewed journal Clinical Therapeutics, distributed in October. The study concludes that patients emerging from orthopedic and abdominal surgeries required less narcotic and experienced less pain with 800 mg of intravenous ibuprofen every six hours compared to morphine alone.

20 Oct 2009

Robotically assisted minimally invasive bladder reconstructive surgery on children performed

For the first time, a surgical robot has been used to perform minimally invasive reconstructive surgery on five children whose bladder was dysfunctional because they were born with spina bifida [incomplete formation of the spine or spinal cord].

18 Oct 2009

Somanetics obtains exclusive sublicense to new cerebral autoregulation technology

Somanetics Corporation today announced that it has signed an Exclusive Sublicense Agreement with Raba Equity Partners II, LLC ("Raba coreFoundry"). Under terms of the agreement, Somanetics has obtained exclusive rights, subject to specified rights of the U.S. Government and rights retained by The Johns Hopkins University, to new cerebral autoregulation technology developed at The Johns Hopkins University.

15 Oct 2009

Meda Pharmaceuticals introduces Onsolis for treating breakthrough cancer pain

Meda Pharmaceuticals Inc. today announced the launch of Onsolis(TM)(fentanyl buccal soluble film) in the U.S. for the management of breakthrough pain (BTP) in patients with cancer, eighteen years of age and older, who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.

13 Oct 2009

QRxPharma signs contractual agreement with Patheon

QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today a contractual agreement with Patheon to manufacture clinical supplies of QRxPharma's controlled release Dual-Opioid(TM) formulation (MoxDuo(TM)CR). MoxDuo(TM)CR is designed to provide 12 hours of pain relief in patients suffering from moderate to severe chronic pain (including cancer, lower back, osteoarthritis and neuropathic).

12 Oct 2009

Nektar Therapeutics presents the results from Phase 2 clinical trial of oral NKTR-118

Nektar Therapeutics presented topline data today from its Phase 2 clinical trial of oral NKTR-118 at the American Academy of Pain Management's (AAPM) 20th Annual Clinical Meeting in Phoenix, Arizona.

12 Oct 2009

Vantia Therapeutics announces the start of Phase II proof-of-concept trials of its VA111913 drug

Vantia Therapeutics today announces that its novel oral small molecule drug for the treatment of dysmenorrhoea (painful menstruation) has entered Phase II proof-of-concept trials. In addition, Vantia announces results of the successful Phase I trial of VA111913, which showed the product candidate to be safe and well tolerated.

6 Oct 2009

YM BioSciences to acquire Cytopia

Cytopia Limited has today announced that Cytopia and Toronto-based YM BioSciences Inc. ("YM") have signed an exclusive and binding Implementation Agreement ("Agreement") in which it is proposed that YM will acquire all of the issued shares and options in Cytopia.

6 Oct 2009

US Treasury Department clears YM BioSciences' nimotuzumab clinical program extension

YM BioSciences Inc. a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, today reported operational and financial results for its fiscal year end, ended June 30, 2009.

25 Sep 2009

NASDAQ halts trading in CombinatoRx's common stock

CombinatoRx, Incorporated (NASDAQ: CRXX) announced that NASDAQ has halted trading in the Company’s common stock today.

23 Sep 2009

FDA committees to review Neuromed’s NDA for Exalgo

CombinatoRx, Incorporated (NASDAQ: CRXX) and Neuromed Pharmaceuticals, Inc., a privately-held biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has posted on its website briefing documents for the September 23, 2009 joint meeting of its Anesthetics and Life Support Advisory Committee and its Drug Safety and Risk Management Advisory Committee.

23 Sep 2009

King Pharmaceuticals achieves milestone: Announces commercial availability of EMBEDA

King Pharmaceuticals(R), Inc. (NYSE: KG) today announced a true milestone as it marks the first commercial availability for EMBEDA(TM) (morphine sulfate and naltrexone hydrochloride) Extended Release Capsules, a long-acting Schedule II opioid analgesic for the management of moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time.

21 Sep 2009

QRxPharma completes its pilot evaluation study investigating the efficacy of MoxDuo capsules

QRxPharma Limited and announced today successful completion of its pilot study to evaluate the analgesic efficacy and safety profile of MoxDuo(TM) IR (immediate release) capsules in patients with moderate to severe pain following total knee replacement surgery.

27 Aug 2009

Biospecifics Technologies reports Q2 2009 financials

BioSpecifics Technologies Corp. (Nasdaq: BSTC), a biopharmaceutical company developing first in class collagenase-based products, today announced its financial results for the second quarter ended June 30, 2009.

12 Aug 2009

New journal integrates the science of medicine with the art of music

In response to a recent surge in studies that integrate medicine and music, SAGE, the world's leading independent academic and professional publisher, is pleased to launch Music and Medicine in July, a new interdisciplinary journal that will incorporate the research that combines the two disciplines.

9 Aug 2009

Adding a drug called neostigmine to epidural analgesia reduces dose needed during labor

Adding a drug called neostigmine to epidural analgesia during labor can reduce the amount of anesthetic drug required, while avoiding potential complications caused by morphine-like "opioid" drugs, according to a study in the August issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).

27 Jul 2009

New system may allow use of xenon to protect newborn brain

Breathing xenon gas can help protect the infant brain from damage caused by oxygen deprivation, but the xenon's high cost and scarcity has precluded its widespread use.